IVVD
Invivyd, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.55
−8.21%Year over year
Reported trailing growth
- Revenue
- +26.3%
- EBITDA
- +2.3%
- EBIT
- +0.9%
- EPS
- +57.1%
- Free cash flow
- +3.2%
- Operating cash flow
- +4.1%
Forward estimates
Based on analyst estimates
- Revenue
- +19.9%
- EBITDA
- -9.1%
- EPS
- +6.2%
Three-year CAGR
- Revenue
- +110.5%
- EBITDA
- +69.8%
- EBIT
- +68.6%
- Net income
- +69.1%
- EPS
- +79.0%
- Free cash flow
- +65.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026